Yahoo Finance • 3 days ago
Atlantic City, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The first-ever NJ Healthy Aging Summit, convened by the Partnership for a Drug-Free New Jersey (PDFNJ) in partnership with the New Jersey Division of Mental Health and Addiction Services... Full story
Yahoo Finance • 5 days ago
With the first three quarters of the calendar year in the books, investors are strolling into October with the major indexes at all-time highs and a more than 20% year-to-date gain in the S&P 500 and Nasdaq Composite. Go back even further,... Full story
Yahoo Finance • 6 days ago
Vertex Pharmaceuticals recently announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for IgA nephropathy, along with key clinical advancements in its kidney disease pipeline. This regulatory milestone may hel... Full story
Yahoo Finance • 6 days ago
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. Thi... Full story
Yahoo Finance • 8 days ago
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth... Full story
Yahoo Finance • 10 days ago
What Happened? Shares of data center products and services company Vertiv (NYSE:VRT) fell 6.2% in the afternoon session after Microsoft announced it had successfully tested a new microfluidic cooling system for data center chips, posing a... Full story
Yahoo Finance • 10 days ago
Investing.com -- Vertiv Holdings Co. (NYSE: VRT) shares fell 7% Tuesday after Microsoft (NASDAQ: MSFT) announced the successful testing of a new microfluidic cooling system for data center chips that could potentially disrupt the thermal m... Full story
Yahoo Finance • 13 days ago
Key Points It is a good time to invest in healthcare stocks. Investors should look into Pfizer and Vertex Pharmaceuticals. Pfizer's financial results and pipeline have improved, which should allow it to overcome upcoming headwinds. Vertex... Full story
Yahoo Finance • 15 days ago
[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images CRISPR Therapeutics (NASDAQ:CRSP [https://seekingalpha.com/symbol/CRSP]) traded higher in the premarket on Thursday after J.P. Morgan initiated its coverage with an Over... Full story
Yahoo Finance • 18 days ago
NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the clos... Full story
Yahoo Finance • 18 days ago
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. Thi... Full story
Yahoo Finance • 18 days ago
VANCOUVER, British Columbia, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce the successful completion of the field component of its Ambient No... Full story
Yahoo Finance • 18 days ago
Key Points The company's book-to-bill ratio suggests significant future growth. The AI/data center capital spending market may well be only in its early innings. 10 stocks we like better than Vertiv › It's no secret that the AI/data cent... Full story
Yahoo Finance • 21 days ago
Key Points A major new deal in the industry confirmed that the lights are all green for the data center infrastructure market. The company is preparing for another surge in growth in the coming years, with the introduction of new data cen... Full story
Yahoo Finance • 22 days ago
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX [https://www.chartmill.com/stock/quote/VRTX]) has appeared as a notable candidate from a screening method that mixes firm fundamental growth measures with encouraging technical breakout formations. T... Full story
Yahoo Finance • 23 days ago
Company Logo The United States Cystic Fibrosis Therapeutics Market is set to grow from an estimated US$ 2.32 billion in 2024 to US$ 4.72 billion by 2033, with an 8.22% CAGR from 2025 to 2033. This growth is driven by advancements in gene... Full story
Yahoo Finance • 26 days ago
Wall Street’s broader market averages finished Friday lower after taking back earlier gains on Friday. At the end of trading the blue-chip Dow(DJI [https://seekingalpha.com/symbol/DJI]) handed back 0.48% while the benchmark S&P 500 (SP500... Full story
Yahoo Finance • 30 days ago
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. Thi... Full story
Yahoo Finance • 30 days ago
Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned 18.58% compared to 17.84% for the Russel... Full story
Yahoo Finance • 30 days ago
Investors seeking growth opportunities without overpaying often turn to the Growth At Reasonable Price (GARP) strategy, which targets companies demonstrating strong expansion potential alongside sensible valuations. One method for identify... Full story